0000885590 2025-08-12 2025-08-12 0000885590 1 2025-08-12 2025-08-12 iso4217:USD pure 0000885590 SC TO SC TO-T EX-FILING FEES N/A BAUSCH HEALTH COMPANIES INC. false 67888790.49 0.0001531 10393.64 10393.64 67888790.49 0 0 10393.64 <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt;border-spacing:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left">*</td> <td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Estimated for purposes of calculating the filing fee only. </div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt;border-spacing:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left"> </td> <td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The transaction value was calculated by adding: (i) the product of (A) the sum of (1) 31,042,581 outstanding shares of common stock (the “Shares”) of DURECT Corporation (“DURECT”); (2) 670,268 Shares that may become outstanding as a result of vesting and settlement of restricted stock units; and (3) 49,067 Shares that may become outstanding as a result of vesting and settlement under DURECT’s 2000 Employee Stock Purchase Plan, as amended; and (B) $1.87, the average of the high and low sales prices per Share on August 8, 2025, as reported by Nasdaq Capital Market LLC (which, for the purposes of calculating the filing fee only, shall be deemed to be the “Reference Price”); <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration:underline;display:inline;">plus</div></div></div> </div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt;border-spacing:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left"> </td> <td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">(ii) the product of (A) 1,010,733, which is the sum of options with an exercise price less than the Reference Price and (B) $1.27, the weighted average exercise price of such options; <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration:underline;display:inline;">plus</div></div></div> </div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt;border-spacing:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left"> </td> <td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">(iii) the product of (A) the sum of (1) 600,000 Shares underlying the specified warrant to purchase Shares, dated February 2023, between DURECT and the specified holder thereto and (2) 2,991,027 Shares underlying the specified warrant to purchase Shares, dated July 2023, between DURECT and the specified holders thereto and (B) the Black-Scholes-based value of the warrants pursuant to the terms of the applicable warrant agreement. </div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt;border-spacing:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left">**</td> <td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The filing fee was calculated in accordance with Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">0-11</div> under the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory for Fiscal Year 2025, effective on October 1, 2024, by multiplying the transaction valuation by 0.00015310. </div></td></tr></table>